Reviewing Hologic (HOLX) and The Competition
Hologic (NASDAQ: HOLX) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare Hologic to related companies based on the strength of its analyst recommendations, valuation, earnings, profitability, institutional ownership, dividends and risk.
Earnings & Valuation
This table compares Hologic and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Hologic||$2.98 billion||$1.01 billion||13.76|
|Hologic Competitors||$2.02 billion||$430.74 million||-66.92|
Hologic has higher revenue and earnings than its competitors. Hologic is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Hologic has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Hologic’s competitors have a beta of 0.89, indicating that their average stock price is 11% less volatile than the S&P 500.
This is a summary of current ratings and price targets for Hologic and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Hologic currently has a consensus price target of $47.77, indicating a potential upside of 29.49%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 6.48%. Given Hologic’s stronger consensus rating and higher probable upside, research analysts plainly believe Hologic is more favorable than its competitors.
Institutional & Insider Ownership
96.4% of Hologic shares are held by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 0.8% of Hologic shares are held by company insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Hologic and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Hologic beats its competitors on 11 of the 13 factors compared.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.